Literature DB >> 30830524

High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis.

Cong Dai1, Min Jiang2, Ming-Jun Sun2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30830524     DOI： 10.1007/s10620-019-05531-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  10 in total

1.  An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis.

Authors:  David J Gibson; Zaid S Heetun; Ciaran E Redmond; Kavin S Nanda; Denise Keegan; Kathryn Byrne; Hugh E Mulcahy; Garret Cullen; Glen A Doherty
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-30       Impact factor: 11.382

2.  Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.

Authors:  D Laharie; A Bourreille; J Branche; M Allez; Y Bouhnik; J Filippi; F Zerbib; G Savoye; L Vuitton; J Moreau; A Amiot; J Cosnes; E Ricart; O Dewit; A Lopez-Sanroman; M Fumery; F Carbonnel; G Bommelaer; B Coffin; X Roblin; G van Assche; M Esteve; M Farkkila; J P Gisbert; P Marteau; S Nahon; M de Vos; J Lambert; J Y Mary; E Louis
Journal:  Gut       Date:  2017-01-04       Impact factor: 23.059

3.  Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.

Authors:  Matthew C Choy; Dean Seah; David M Faleck; Shailja C Shah; Che-Yung Chao; Yoon-Kyo An; Graham Radford-Smith; Talat Bessissow; Marla C Dubinsky; Alexander C Ford; Leonid Churilov; Neville D Yeomans; Peter P De Cruz
Journal:  Inflamm Bowel Dis       Date:  2019-06-18       Impact factor: 5.325

4.  Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.

Authors:  Johannan F Brandse; Gijs R van den Brink; Manon E Wildenberg; Desiree van der Kleij; Theo Rispens; Jeroen M Jansen; Ron A Mathôt; Cyriel Y Ponsioen; Mark Löwenberg; Geert R A M D'Haens
Journal:  Gastroenterology       Date:  2015-04-25       Impact factor: 22.682

5.  Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis.

Authors:  Jeffrey A Berinstein; Calen A Steiner; Randolph E Regal; John I Allen; Jami A R Kinnucan; Ryan W Stidham; Akbar K Waljee; Shrinivas Bishu; Leslie B Aldrich; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-17       Impact factor: 11.382

6.  High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival.

Authors:  Che-Yung Chao; Alex Al Khoury; Achuthan Aruljothy; Sophie Restellini; Jonathan Wyse; Waqqas Afif; Alain Bitton; Peter L Lakatos; Talat Bessissow
Journal:  Dig Dis Sci       Date:  2018-11-16       Impact factor: 3.199

7.  Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.

Authors:  B Ungar; Y Mazor; R Weisshof; H Yanai; Y Ron; I Goren; A Waizbard; M Yavzori; E Fudim; O Picard; R Loebstein; U Kopylov; I Dotan; Y Chowers; R Eliakim; S Ben-Horin
Journal:  Aliment Pharmacol Ther       Date:  2016-04-19       Impact factor: 8.171

8.  Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis?

Authors:  Hans H Herfarth; Gerhard Rogler; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2014-10-05       Impact factor: 11.382

9.  Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.

Authors:  Stephen Hanauer; Remo Panaccione; Silvio Danese; Adam Cheifetz; Walter Reinisch; Peter D R Higgins; Deborah A Woodworth; Haiying Zhang; Gary S Friedman; Nervin Lawendy; Daniel Quirk; Chudy I Nduaka; Chinyu Su
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-10       Impact factor: 11.382

10.  Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study.

Authors:  Lauren Beswick; Ourania Rosella; Gennaro Rosella; Belinda Headon; Miles P Sparrow; Peter R Gibson; Daniel R van Langenberg
Journal:  J Crohns Colitis       Date:  2018-02-28       Impact factor: 9.071
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.